Compare HNRG & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNRG | RGNX |
|---|---|---|
| Founded | 1949 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.0M | 487.2M |
| IPO Year | 1995 | 2015 |
| Metric | HNRG | RGNX |
|---|---|---|
| Price | $10.38 | $7.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $28.00 | $21.40 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.78 | 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $469,466,000.00 | $10,393,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 16.09 | ★ 126.48 |
| 52 Week Low | $8.85 | $5.46 |
| 52 Week High | $23.44 | $16.19 |
| Indicator | HNRG | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 49.11 |
| Support Level | $8.85 | $6.79 |
| Resistance Level | $12.11 | $8.31 |
| Average True Range (ATR) | 0.72 | 0.60 |
| MACD | 0.13 | 0.08 |
| Stochastic Oscillator | 47.30 | 43.79 |
Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.